-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca Presents New Preclinical Data For Profiles Of RAS-Targeting Franchise At 2025 AACR Annual Meeting

Benzinga·04/29/2025 20:09:51
Listen to the news

ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling